221 related articles for article (PubMed ID: 35258435)
21. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
[TBL] [Abstract][Full Text] [Related]
22. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
[TBL] [Abstract][Full Text] [Related]
24. Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
Bustamante P; Miyamoto D; Goyeneche A; de Alba Graue PG; Jin E; Tsering T; Dias AB; Burnier MN; Burnier JV
Cancer Med; 2019 Dec; 8(17):7265-7277. PubMed ID: 31588689
[TBL] [Abstract][Full Text] [Related]
25. Landscape of Infiltrated Immune Cell Characterization in Uveal Melanoma to Improve Immune Checkpoint Blockade Therapy.
Lv X; Ding M; Liu Y
Front Immunol; 2022; 13():848455. PubMed ID: 35309331
[TBL] [Abstract][Full Text] [Related]
26. Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.
Goh AY; Layton CJ
Clin Exp Ophthalmol; 2016 Aug; 44(6):509-19. PubMed ID: 26601795
[TBL] [Abstract][Full Text] [Related]
27. Liver metastasis in uveal melanoma - treatment options and clinical outcome.
Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A
Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015
[TBL] [Abstract][Full Text] [Related]
28. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
30. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer.
Liu C; Wang P; Sun Y; Dou X; Hu X; Zou W; Sun Y; Hu Q; Yue J
Front Oncol; 2022; 12():756811. PubMed ID: 35530332
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab activity in advanced uveal melanoma.
Khattak MA; Fisher R; Hughes P; Gore M; Larkin J
Melanoma Res; 2013 Feb; 23(1):79-81. PubMed ID: 23211837
[TBL] [Abstract][Full Text] [Related]
33. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Jespersen H; Olofsson Bagge R; Ullenhag G; Carneiro A; Helgadottir H; Ljuslinder I; Levin M; All-Eriksson C; Andersson B; Stierner U; Nilsson LM; Nilsson JA; Ny L
BMC Cancer; 2019 May; 19(1):415. PubMed ID: 31046743
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Uveal Melanoma.
Shoushtari AN; Carvajal RD
Cancer Treat Res; 2016; 167():281-93. PubMed ID: 26601868
[TBL] [Abstract][Full Text] [Related]
35. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
36. Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures.
Gao G; Yu Z; Zhao X; Fu X; Liu S; Liang S; Deng A
Sci Rep; 2021 Nov; 11(1):22244. PubMed ID: 34782661
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.
Mignard C; Deschamps Huvier A; Gillibert A; Duval Modeste AB; Dutriaux C; Khammari A; Avril MF; Kramkimel N; Mortier L; Marcant P; Lesimple T; Gaudy-Marqueste C; Lesage C; Machet L; Aubin F; Meyer N; Beneton N; Jeudy G; Montaudié H; Arnault JP; Visseaux L; Trabelsi S; Amini-Adle M; Maubec E; Le Corre Y; Lipsker D; Wierzbicka-Hainaut E; Litrowski N; Stefan A; Brunet-Possenti F; Leccia MT; Joly P
J Oncol; 2018; 2018():1908065. PubMed ID: 30631354
[TBL] [Abstract][Full Text] [Related]
38. sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
Barak V; Kalickman I; Pe'er J
Anticancer Res; 2022 Mar; 42(3):1447-1453. PubMed ID: 35220238
[TBL] [Abstract][Full Text] [Related]
39. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
40. KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma.
Zhang J; Zhang J; Guan J; Yu L; Yan S
Dis Markers; 2022; 2022():1930185. PubMed ID: 36046379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
